pulcherriminic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
pulcherriminic acid : A pyrazine N-oxide that is pyrazine-1,4-dioxide substituted at positions 2 and 5 by hydroxy groups and at positions 3 and 6 by isobutyl groups. Formed by oxidative aromatisation of cyclo(L-leucyl-L-leucyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 3083664 |
| CHEBI ID | 71599 |
| MeSH ID | M0053515 |
| Synonym |
|---|
| 2,5-pyrazinediol, 3,6-bis(2-methylpropyl)-, 1,4-dioxide |
| 2,5-diisobutyl-3,6-dihydroxy-pyrazine-1,4-dioxide |
| 957-86-8 |
| pulcherriminic acid |
| 1,5-dihydroxy-3,6-bis(2-methylpropyl)-4-oxidopyrazin-4-ium-2-one |
| 2,5-dihydroxy-3,6-bis(2-methylpropyl)pyrazine bis-n-oxide |
| C20515 |
| CHEBI:71599 |
| 3,6-diisobutylpyrazine-2,5-diol 1,4-dioxide |
| HY-N10473 |
| CS-0535026 |
Pulcherriminic acid is a cyclic dipeptide. It is found mainly in the human body.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pulcherriminic acid is a cyclic dipeptide found mainly in " | ( Research Progress of the Biosynthesis of Natural Bio-Antibacterial Agent Pulcherriminic Acid in Li, Y; Liu, J; Yong, X; Yuan, S; Zhao, T, 2020) | 2.23 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.63) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||